Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats.
The present study aimed at evaluating the efficacy of lacosamide (0.3 to 30 mg/kg), a new anticonvulsant drug, in a model of essential tremor in comparison to the reference compounds propranolol and primidone. We observed a high tremorlytic effect of lacosamide reducing the intensity of tremors following harmaline administration in a dose-dependent manner. The highest dose also modified the latency and intensity of tremor at onset. The effect of lacosamide was equal or even superior to propranolol and primidone indicating that lacosamide may be a new antitremorgenic drug that merits further clinical investigation.
Stöhr
Thomas
T
Schwarz Biosciences GmbH, Department of Pharmacology, Monheim, Germany. stoehr@bitop.de <stoehr@bitop.de>
Lekieffre
Delphine
D
Freitag
Joachim
J
D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D020329:Essential Tremor / Q000139:chemically induced / Q000517:prevention & control*; D006246:Harmaline; D000078334:Lacosamide; D008297:Male; D011324:Primidone / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time
D000081:Acetamides; D000927:Anticonvulsants; D011324:Primidone; D000078334:Lacosamide; D011433:Propranolol; D006246:Harmaline